Spot Bitcoin ETFs in the U.S. recorded $3.05 million in net inflows on Thursday, breaking a 13-day streak of withdrawals that had removed over $4.4 billion since mid-May. BlackRock’s IBIT led the inflows with $47.66 million, while other funds like Fidelity and Ark Invest continued to see outflows. Despite the inflow, total assets under management dropped from $104.29 billion to $80.40 billion during the outflow period, coinciding with Bitcoin's price fall from above $74,000 to below $64,000. Spot Ether ETFs also returned to positive flows, and Hyperliquid ETFs maintained continuous inflows. Market volatility remains, with Bitcoin prices fluctuating near $61,000 after a recent low around $59,100. Analysts suggest ETF demand plays a significant role in Bitcoin's price movements, highlighting the impact of sustained ETF withdrawals earlier this year.
Grail's stock surged 55% in one week following a positive FDA advisory committee vote on its Galleri multi-cancer early detection test, which was deemed safe and beneficial. Analyst Kyle Mikson raised the price target from $80 to $150, reflecting str...
Roblox stock fell 6% following Jefferies' downgrade to Underperform and a price target cut to $38, citing concerns over overly optimistic bookings outlook and slower user growth in the US and Canada. This downgrade contrasts with steady performance i...
Geely Holding Group has acquired a 30% stake in Nio Power, the battery swapping and charging unit of Nio, valuing the business at about RMB16 billion. This investment marks a significant external validation of Nio's battery swapping network, a key as...
CoreWeave reported strong Q2 results with significant scale and margin improvements, supported by a $104.2 billion backlog driven by demand from hyperscalers exceeding supply. The company raised its 2026 revenue guidance to $12.4–$13.2 billion, expec...
Tiziana Life Sciences has dosed the first three patients in a Phase 2a trial testing foralumab, a nasal spray antibody, for treating early-stage ALS. The Healey ALS MyMatch BANYAN trial will enroll 44 patients to evaluate safety, tolerability, and im...
